Retatrutide is a synthetic triple-receptor agonist peptide targeting the GLP-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR) simultaneously, studied extensively across metabolic biology, obesity research, energy expenditure, and cardiovascular science for its unmatched tri-agonist incretin action and superior metabolic influence compared to single and dual-receptor compounds making it the most advanced and broadly acting incretin research peptide currently available in modern metabolic science
Always consult available research protocols
Gut changes occur Progesterone + estrogen fluctuations affect motility, microbiome stability, and satiety signals
Retatrutide, like most peptides, degrades when exposed to heat, light, or improper handling
That holds for Ozempic and it will hold for retatrutide
After the intro period, Wegovy pens at any dose from 0.25 mg through 2.4 mg cost $349 per month, and the higher-dose HD 7.2 mg pen is $399 per month